A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Trial Profile

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2018

At a glance

  • Drugs Pegzilarginase (Primary) ; Pembrolizumab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 08 May 2018 According to an Aeglea Biotherapeutics media release, the company expects to initiate the phase 2 part of this study in the third quarter of 2018.
    • 02 Apr 2018 According to an Aeglea Biotherapeutics media release, company announced the dosing of first patient and expect to report topline data in the fourth quarter of this year.
    • 22 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top